GlassScriptPhysician profile
Milay Luis Lam
NPI 1205174430
$8,435.37
in general payments reported to CMS, 2019-2025
23 companies · $1,031 in 2025
The $1,031 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276 · 2021: $570 · 2022: $411 · 2023: $461 · 2024: $5,687 · 2025: $1,031.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,200 · Food and Beverage: $2,693 · Travel and Lodging: $1,286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,200.00 |
| Food and Beverage | $2,692.61 |
| Travel and Lodging | $1,286.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $4,903.06 | 2021-2025 | |
| Novo Nordisk INC | $1,079.55 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $535.61 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Medtronic, INC. | $319.25 | 2024-2025 | Minimed 780g, Inceptiv |
| Medtronic Minimed, INC. | $275.92 | 2019 | |
| Abbott Laboratories | $241.66 | 2022-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $217.22 | 2021-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Astellas Pharma US INC | $188.54 | 2024-2025 | Veozah |
| Radius Health, INC. | $124.96 | 2024-2025 | Tymlos |
| Insulet Corporation | $117.22 | 2022-2024 | Omnipod |
| Cequr Corporation | $112.82 | 2024 | Cequr Simplicity |
| Bayer Healthcare Pharmaceuticals INC. | $56.84 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $44.90 | 2024 | Strensiq |
| Corcept Therapeutics | $44.00 | 2024-2025 | Korlym |
| Madrigal Pharmaceuticals | $30.62 | 2025 | Rezdiffra |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ionis Pharmaceuticals, INC. | $21.83 | 2025 | Tryngolza |
| Ipsen Biopharmaceuticals, INC | $20.52 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.36 | 2022 | |
| Sequel Med Tech, LLC | $18.21 | 2025 | Twiist |
| Astrazeneca Pharmaceuticals LP | $17.65 | 2021 | |
| Lifescan, INC. | $17.56 | 2021 | |
| Kvk-Tech, INC. | $14.39 | 2021-2022 | |
| Tolmar, INC. | $13.68 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Milay Luis Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.